# ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

> **NCT01472146** · PHASE2 · COMPLETED · sponsor: **Susanne Crocamo** · enrollment: 58 (actual)

## Conditions studied

- Breast Cancer
- Breast Disease
- Neoplasms
- Neoplasms by Site

## Interventions

- **DRUG:** Zo-Nantax

## Key facts

- **NCT ID:** NCT01472146
- **Lead sponsor:** Susanne Crocamo
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2016-07
- **Final completion:** 2017-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472146, "ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01472146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*